## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.60)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses**
- Source: PR Newswire | 20260106T130149 | Bullish | Relevance: 100%
- CooperVision is set to launch its MyDay® MiSight® 1 day contact lenses in the UK and other European markets. These new lenses combine the established MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material of MyDay® lenses to help slow the progression of myopia in children. The company emphasizes its commitment to myopia management, highlighting that this innovation provides "always-on" myopia control and aids in transitioning wearers to adult lenses due to shared material specifications.

**2. Is It Too Late To Consider Buying The Cooper Companies, Inc. (NASDAQ:COO)?**
- Source: Simply Wall Street | 20260106T143548 | Somewhat-Bullish | Relevance: 100%
- Cooper Companies, Inc. (NASDAQ:COO) recently saw a 22% share price rise, bringing it closer to its fair value. With profit expected to grow by 99% over the next couple of years, the company has a bright future outlook. While the stock appears fairly valued currently, its volatility based on a high beta could present future buying opportunities.

**3. CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses**
- Source: PR Newswire UK | 20260106T130827 | Bullish | Relevance: 100%
- CooperVision is set to launch its new MyDay® MiSight® 1 day contact lenses in the UK and select European markets. These lenses combine advanced silicone hydrogel material with the proven ActivControl® Technology to slow the worsening of myopia in children. This expansion aims to enhance CooperVision's evidence-based myopia management portfolio, offering "always-on" myopia control.

**4. Hologic Trading Near 52-Week High: How Should You Play the Stock?**
- Source: Finviz | 20260105T135404 | Neutral | Relevance: 67%
- Hologic's shares closed near their 52-week high, outperforming its industry and sector, driven by strong growth in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, alongside a proposed $18.3 billion take-private deal. Despite macroeconomic headwinds and tariffs, the company's innovation, clinical evidence, and regulatory approvals suggest a "hold" position for current investors due to its favorable price performance and appealing valuation. Prospective buyers are advised to wait for more clarity.

**5. Hologic Trading Near 52-Week High: How Should You Play the Stock?**
- Source: Yahoo Finance | 20260105T071700 | Somewhat-Bullish | Relevance: 62%
- Hologic's shares closed near their 52-week high, outperforming its industry and the S&P 500, partly due to a proposed $18.3 billion take-private deal. The company benefits from strong performance in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, supported by strategic acquisitions and AI advancements. Despite macroeconomic concerns like tariffs and challenges in China, Hologic maintains a "Hold" rating due to its growth drivers, clinical evidence, and appealing valuation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 10 ($1.30M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- Momentum building: MRS_10 improving +2.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Analyst sentiment positive (3 raises, avg +14%). Insider buying signal ($1.3M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.8B |
| Beta | 1.03 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 17.1 |
| Current P/E | 18.7 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.5% to 1.6% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.58% (CS: 54) | Neutral |
| RSI_14 | 66.0 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.100x | Above |
| vs SMA200 | 1.131x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $84.32
- **Stop Loss:** $80.60 (4.4% risk)
- **Target:** $88.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 354
- **Position Value:** $29,849.28
- **Portfolio %:** 29.85%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*